TONIX PHARMACEUTICALS HOLDING CORP. (NASDAQ:TNXP) Files An 8-K Regulation FD Disclosure
Tonix Pharmaceuticals Holding Corp. (the “Company”) updated its investor presentations, which are used to conduct meetings with investors, stockholders and analysts and at investor conferences, and which the Company intends to place on its website, which may contain nonpublic information. Copies of the presentations are filed as Exhibits 99.01 and 99.02 hereto and incorporated herein by reference.
The information in this Item 7.01 of this Current Report on Form 8-K, including Exhibits 99.01 and 99.02 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the United States Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the United States Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Tonix Pharmaceuticals Holding Corp. Exhibit
EX-99.01 2 ex99-01.htm CORPORATE PRESENTATION FOR NOVEMBER 2019 (LONG FORM) Tonix Pharmaceuticals Holding Corp. 8-K Exhibit 99.01 © 2019 Tonix Pharmaceuticals Holding Corp. November 2019 Version P0203 11 – 4 – 19 (Doc 0549) Investor Presentation © 2019 Tonix Pharmaceuticals Holding Corp. 2 Cautionary Note on Forward – Looking Statements Certain statements in this presentation regarding strategic plans,…
To view the full exhibit click